Quince Therapeutics, Inc.
QNCX
$1.63
$0.021.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.55M | 14.90M | 15.08M | 15.91M | 16.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.98M | 37.93M | 33.67M | 31.90M | 29.45M |
| Operating Income | -38.98M | -37.93M | -33.67M | -31.90M | -29.45M |
| Income Before Tax | -48.90M | -60.61M | -56.74M | -53.13M | -53.01M |
| Income Tax Expenses | 134.00K | 103.00K | 87.00K | 131.00K | 118.00K |
| Earnings from Continuing Operations | -49.03 | -60.71 | -56.83 | -53.26 | -53.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.03M | -60.71M | -56.83M | -53.26M | -53.12M |
| EBIT | -38.98M | -37.93M | -33.67M | -31.90M | -29.45M |
| EBITDA | -38.82M | -37.75M | -33.48M | -31.43M | -29.06M |
| EPS Basic | -1.10 | -1.40 | -1.31 | -1.25 | -1.27 |
| Normalized Basic EPS | -0.60 | -0.51 | -0.45 | -0.41 | -0.39 |
| EPS Diluted | -1.10 | -1.40 | -1.31 | -1.25 | -1.27 |
| Normalized Diluted EPS | -0.60 | -0.51 | -0.45 | -0.41 | -0.39 |
| Average Basic Shares Outstanding | 177.57M | 173.98M | 173.05M | 170.40M | 163.30M |
| Average Diluted Shares Outstanding | 177.57M | 173.98M | 173.05M | 170.40M | 163.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |